Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions
Objective—To assess the safety, tolerability and efficacy of low‐dose ketoprofen (75–150 mg daily for 5 to 15 days) in a general practice setting. Design—Open label, non‐controlled study of ketoprofen 25 mg tablets in the treatment of pain in ENT diseases, dysmenorrhoea, and musculoskeletal disorder...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 1996-09, Vol.5 (5), p.295-302 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 302 |
|---|---|
| container_issue | 5 |
| container_start_page | 295 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 5 |
| creator | Moore, Nicholas Vuillemin, Nicole Abiteboul, Michel Boudignat, Odile Paliwoda, André Robin, Jean-Louis Jacobs, Laurent-Didier |
| description | Objective—To assess the safety, tolerability and efficacy of low‐dose ketoprofen (75–150 mg daily for 5 to 15 days) in a general practice setting.
Design—Open label, non‐controlled study of ketoprofen 25 mg tablets in the treatment of pain in ENT diseases, dysmenorrhoea, and musculoskeletal disorders.
Setting—General practice, 600 investigators
Subjects—Four thousand and sixty‐eight patients, aged 13–93 years, mean 42.3 years, 1009 with ENT diseases (mean age 38.8 (13–83) years, 53% female), 978 with dysmenorrhoea (mean age 30.3 (13–60) years, 100% female), 2081 with musculoskeletal disorders (mean age 49.6 (16–93) years, 54% female).
Main outcome measures—Occurrence of adverse events, on patient and physician evaluation; dose and duration of treatment prescribed/taken (diary); global evaluation of efficacy by patient and physician.
Result—Twenty‐two patients were lost to follow‐up ( |
| doi_str_mv | 10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77907305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77907305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3183-e97f54e8cd628a146ec6a2d6193b94f14adf2bbbd21b2bfd6aec190a95f3b3dc3</originalsourceid><addsrcrecordid>eNp9kFtv0zAYhi0EYmPwF5CvUHuR4kOcxOUgTek6Kio6qUMTV58cH6ZAmow4EfRP8SP2y3CUqrtgQpZ8_L73ff0g9IGSGSWEvZ1sV_lqSomUERUinVApEyKnYi7eMynm8_PVIrpabBnnH_mMzPLNOxaRJ-j02PF02AseZSKRJ-iF998JCW8yfo5OqCApz6g4Rd_Wqr21eKtVFWblbLfH2643e9w4_Nl2zV3bOFtjJvDuFk-uw9nq-z9TXNZ4aYu2DG2qNvhKlbXrK5w3tSm7sqn9S_TMqcrbV4f1DH1dXlznn6L15nKVn68jzWnGIytTJ2KbaZOwTNE4sTpRzCRU8kLGjsbKOFYUhWG0YIUzibKaSqKkcLzgRvMz9GbUDUl_9tZ3sCu9tlWlatv0HtJUhs8GEscAum28b62Du7bcqXYPlMDAHGBgDgNBGAjCyBxEGIE5QGAOI3PgQCDfAAMSdF8fAvTFzpoH1QPkUHAzFvwKtPb_uP7f9FHPw01Qjkbl0nf291FZtT8gSXkq4ObLJRBB1pwtM1jwv9khq3I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77907305</pqid></control><display><type>article</type><title>Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Moore, Nicholas ; Vuillemin, Nicole ; Abiteboul, Michel ; Boudignat, Odile ; Paliwoda, André ; Robin, Jean-Louis ; Jacobs, Laurent-Didier</creator><creatorcontrib>Moore, Nicholas ; Vuillemin, Nicole ; Abiteboul, Michel ; Boudignat, Odile ; Paliwoda, André ; Robin, Jean-Louis ; Jacobs, Laurent-Didier</creatorcontrib><description>Objective—To assess the safety, tolerability and efficacy of low‐dose ketoprofen (75–150 mg daily for 5 to 15 days) in a general practice setting.
Design—Open label, non‐controlled study of ketoprofen 25 mg tablets in the treatment of pain in ENT diseases, dysmenorrhoea, and musculoskeletal disorders.
Setting—General practice, 600 investigators
Subjects—Four thousand and sixty‐eight patients, aged 13–93 years, mean 42.3 years, 1009 with ENT diseases (mean age 38.8 (13–83) years, 53% female), 978 with dysmenorrhoea (mean age 30.3 (13–60) years, 100% female), 2081 with musculoskeletal disorders (mean age 49.6 (16–93) years, 54% female).
Main outcome measures—Occurrence of adverse events, on patient and physician evaluation; dose and duration of treatment prescribed/taken (diary); global evaluation of efficacy by patient and physician.
Result—Twenty‐two patients were lost to follow‐up (<1%); dose effectively taken was lower than prescribed (3.3 versus 3.6 tablets/day); treatment was stopped prematurely in 3.3% of patients because of adverse events, in 17.1% because of early success of therapy. Gastrointestinal adverse events (AE) were the most frequent (76%) of AE), occurring in 10% of patients. They were more frequent in patients with musculoskeletal pain, who were older and had more associated diseases. Five patients were hospitalized, two for preplanned hospitalizations, the others for one asthma attack, one worsening of low back pain, and one angina attack, none attributed to treatment by the GP. None of the AE was life‐threatening. Identified risk factors for AE were age and previous medical history, especially of gastrointestinal disorders.
Conclusions—Good quality large scale studies with little or no loss to follow‐up can be done in a general practice setting. At the dose used, ketoprofen was generally well tolerated, and used at a lower dose than prescribed, it was not associated with severe or new side‐effects. The results of this study could justify its use in self‐medication in these indications.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0</identifier><identifier>PMID: 15073815</identifier><language>eng</language><publisher>Chichester: John Wiley & Sons, Ltd</publisher><subject>adverse events ; analgesics ; ketoprofen ; NSAIDS ; postmarketing cohort study ; risk factors</subject><ispartof>Pharmacoepidemiology and drug safety, 1996-09, Vol.5 (5), p.295-302</ispartof><rights>Copyright © 1996 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291099-1557%28199609%295%3A5%3C295%3A%3AAID-PDS233%3E3.0.CO%3B2-0$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291099-1557%28199609%295%3A5%3C295%3A%3AAID-PDS233%3E3.0.CO%3B2-0$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15073815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moore, Nicholas</creatorcontrib><creatorcontrib>Vuillemin, Nicole</creatorcontrib><creatorcontrib>Abiteboul, Michel</creatorcontrib><creatorcontrib>Boudignat, Odile</creatorcontrib><creatorcontrib>Paliwoda, André</creatorcontrib><creatorcontrib>Robin, Jean-Louis</creatorcontrib><creatorcontrib>Jacobs, Laurent-Didier</creatorcontrib><title>Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidem. Drug Safe</addtitle><description>Objective—To assess the safety, tolerability and efficacy of low‐dose ketoprofen (75–150 mg daily for 5 to 15 days) in a general practice setting.
Design—Open label, non‐controlled study of ketoprofen 25 mg tablets in the treatment of pain in ENT diseases, dysmenorrhoea, and musculoskeletal disorders.
Setting—General practice, 600 investigators
Subjects—Four thousand and sixty‐eight patients, aged 13–93 years, mean 42.3 years, 1009 with ENT diseases (mean age 38.8 (13–83) years, 53% female), 978 with dysmenorrhoea (mean age 30.3 (13–60) years, 100% female), 2081 with musculoskeletal disorders (mean age 49.6 (16–93) years, 54% female).
Main outcome measures—Occurrence of adverse events, on patient and physician evaluation; dose and duration of treatment prescribed/taken (diary); global evaluation of efficacy by patient and physician.
Result—Twenty‐two patients were lost to follow‐up (<1%); dose effectively taken was lower than prescribed (3.3 versus 3.6 tablets/day); treatment was stopped prematurely in 3.3% of patients because of adverse events, in 17.1% because of early success of therapy. Gastrointestinal adverse events (AE) were the most frequent (76%) of AE), occurring in 10% of patients. They were more frequent in patients with musculoskeletal pain, who were older and had more associated diseases. Five patients were hospitalized, two for preplanned hospitalizations, the others for one asthma attack, one worsening of low back pain, and one angina attack, none attributed to treatment by the GP. None of the AE was life‐threatening. Identified risk factors for AE were age and previous medical history, especially of gastrointestinal disorders.
Conclusions—Good quality large scale studies with little or no loss to follow‐up can be done in a general practice setting. At the dose used, ketoprofen was generally well tolerated, and used at a lower dose than prescribed, it was not associated with severe or new side‐effects. The results of this study could justify its use in self‐medication in these indications.</description><subject>adverse events</subject><subject>analgesics</subject><subject>ketoprofen</subject><subject>NSAIDS</subject><subject>postmarketing cohort study</subject><subject>risk factors</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNp9kFtv0zAYhi0EYmPwF5CvUHuR4kOcxOUgTek6Kio6qUMTV58cH6ZAmow4EfRP8SP2y3CUqrtgQpZ8_L73ff0g9IGSGSWEvZ1sV_lqSomUERUinVApEyKnYi7eMynm8_PVIrpabBnnH_mMzPLNOxaRJ-j02PF02AseZSKRJ-iF998JCW8yfo5OqCApz6g4Rd_Wqr21eKtVFWblbLfH2643e9w4_Nl2zV3bOFtjJvDuFk-uw9nq-z9TXNZ4aYu2DG2qNvhKlbXrK5w3tSm7sqn9S_TMqcrbV4f1DH1dXlznn6L15nKVn68jzWnGIytTJ2KbaZOwTNE4sTpRzCRU8kLGjsbKOFYUhWG0YIUzibKaSqKkcLzgRvMz9GbUDUl_9tZ3sCu9tlWlatv0HtJUhs8GEscAum28b62Du7bcqXYPlMDAHGBgDgNBGAjCyBxEGIE5QGAOI3PgQCDfAAMSdF8fAvTFzpoH1QPkUHAzFvwKtPb_uP7f9FHPw01Qjkbl0nf291FZtT8gSXkq4ObLJRBB1pwtM1jwv9khq3I</recordid><startdate>199609</startdate><enddate>199609</enddate><creator>Moore, Nicholas</creator><creator>Vuillemin, Nicole</creator><creator>Abiteboul, Michel</creator><creator>Boudignat, Odile</creator><creator>Paliwoda, André</creator><creator>Robin, Jean-Louis</creator><creator>Jacobs, Laurent-Didier</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199609</creationdate><title>Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions</title><author>Moore, Nicholas ; Vuillemin, Nicole ; Abiteboul, Michel ; Boudignat, Odile ; Paliwoda, André ; Robin, Jean-Louis ; Jacobs, Laurent-Didier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3183-e97f54e8cd628a146ec6a2d6193b94f14adf2bbbd21b2bfd6aec190a95f3b3dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>adverse events</topic><topic>analgesics</topic><topic>ketoprofen</topic><topic>NSAIDS</topic><topic>postmarketing cohort study</topic><topic>risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moore, Nicholas</creatorcontrib><creatorcontrib>Vuillemin, Nicole</creatorcontrib><creatorcontrib>Abiteboul, Michel</creatorcontrib><creatorcontrib>Boudignat, Odile</creatorcontrib><creatorcontrib>Paliwoda, André</creatorcontrib><creatorcontrib>Robin, Jean-Louis</creatorcontrib><creatorcontrib>Jacobs, Laurent-Didier</creatorcontrib><collection>Istex</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moore, Nicholas</au><au>Vuillemin, Nicole</au><au>Abiteboul, Michel</au><au>Boudignat, Odile</au><au>Paliwoda, André</au><au>Robin, Jean-Louis</au><au>Jacobs, Laurent-Didier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidem. Drug Safe</addtitle><date>1996-09</date><risdate>1996</risdate><volume>5</volume><issue>5</issue><spage>295</spage><epage>302</epage><pages>295-302</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Objective—To assess the safety, tolerability and efficacy of low‐dose ketoprofen (75–150 mg daily for 5 to 15 days) in a general practice setting.
Design—Open label, non‐controlled study of ketoprofen 25 mg tablets in the treatment of pain in ENT diseases, dysmenorrhoea, and musculoskeletal disorders.
Setting—General practice, 600 investigators
Subjects—Four thousand and sixty‐eight patients, aged 13–93 years, mean 42.3 years, 1009 with ENT diseases (mean age 38.8 (13–83) years, 53% female), 978 with dysmenorrhoea (mean age 30.3 (13–60) years, 100% female), 2081 with musculoskeletal disorders (mean age 49.6 (16–93) years, 54% female).
Main outcome measures—Occurrence of adverse events, on patient and physician evaluation; dose and duration of treatment prescribed/taken (diary); global evaluation of efficacy by patient and physician.
Result—Twenty‐two patients were lost to follow‐up (<1%); dose effectively taken was lower than prescribed (3.3 versus 3.6 tablets/day); treatment was stopped prematurely in 3.3% of patients because of adverse events, in 17.1% because of early success of therapy. Gastrointestinal adverse events (AE) were the most frequent (76%) of AE), occurring in 10% of patients. They were more frequent in patients with musculoskeletal pain, who were older and had more associated diseases. Five patients were hospitalized, two for preplanned hospitalizations, the others for one asthma attack, one worsening of low back pain, and one angina attack, none attributed to treatment by the GP. None of the AE was life‐threatening. Identified risk factors for AE were age and previous medical history, especially of gastrointestinal disorders.
Conclusions—Good quality large scale studies with little or no loss to follow‐up can be done in a general practice setting. At the dose used, ketoprofen was generally well tolerated, and used at a lower dose than prescribed, it was not associated with severe or new side‐effects. The results of this study could justify its use in self‐medication in these indications.</abstract><cop>Chichester</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15073815</pmid><doi>10.1002/(SICI)1099-1557(199609)5:5<295::AID-PDS233>3.0.CO;2-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 1996-09, Vol.5 (5), p.295-302 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77907305 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | adverse events analgesics ketoprofen NSAIDS postmarketing cohort study risk factors |
| title | Large Scale Safety Study of Ketoprofen 25 mg (Toprec®) in Febrile and Painful Conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A24%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Large%20Scale%20Safety%20Study%20of%20Ketoprofen%2025%20mg%20(Toprec%C2%AE)%20in%20Febrile%20and%20Painful%20Conditions&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Moore,%20Nicholas&rft.date=1996-09&rft.volume=5&rft.issue=5&rft.spage=295&rft.epage=302&rft.pages=295-302&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/(SICI)1099-1557(199609)5:5%3C295::AID-PDS233%3E3.0.CO;2-0&rft_dat=%3Cproquest_cross%3E77907305%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77907305&rft_id=info:pmid/15073815&rfr_iscdi=true |